妊娠糖尿病の世界市場レポート 2025年

妊娠糖尿病市場規模は、今後数年間で力強い成長が見込まれます。2029年には、CAGR9.0％で129億米ドルに成長します。予測期間中に予測される成長は、肥満の有病率の増加、クラウドベースのプロジェクトソリューションの採用拡大、関連機器やアプリケーションの使用増加など、さまざまな要因によってもたらされます。さらに、不健康なライフスタイルの選択による糖尿病患者の急増、公衆衛生意識の高まり、糖尿病率の上昇も大きな要因です。この期間に予想される主な動向には、デジタル糖尿病管理アプリの出現、クローズドループ制御システム、糖尿病管理技術の進歩、酵素イノベーション、その他の最先端医療の進歩などがあります。

肥満の有病率の増加は、今後の妊娠糖尿病市場の拡大を牽引すると予想されます。肥満とは、体格指数（BMI）が30以上の個人を指し、重大な健康リスクにつながる過剰な体脂肪を示しています。肥満の増加は、座りがちなライフスタイル、高カロリー加工食品の摂取量の増加、遺伝的素因、健康的な食品や運動オプションへのアクセス制限などの要因に影響されています。インスリン抵抗性や妊娠中の過度な体重増加のリスクが高まるため、放っておくと母子ともに合併症を引き起こす可能性があります。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）は2024年3月、2022年には世界の約8人に1人が肥満とともに生活していると報告しました。この中には、太りすぎに分類される18歳以上の成人25億人が含まれ、そのうち8億9,000万人が肥満とともに暮らしています。成人のうち43％が過体重、16％が肥満でした。さらに、5歳未満の子どものうち3,700万人が太りすぎ、5歳から19歳の子ども・青年のうち3億9,000万人以上が太りすぎで、うち1億6,000万人が肥満とともに暮らしていました。その結果、肥満人口の増加が妊娠糖尿病市場の成長を牽引しています。

妊娠糖尿病市場の主要企業は、診断キットのような先進製品の市場開拓に注力しており、症状の早期発見のための迅速、正確、便利な方法を提供しています。妊娠糖尿病用診断キットは、妊婦の血糖値測定や耐糖能異常の検出に使用される医療ツールで、症状の早期発見と管理に役立ちます。例えば、2024年8月、オーストリアに本社を置くバイオテクノロジー企業であるDirectSens GmbH社は、XpressGT RUOキットを発表しました。この診断キットは、妊娠糖尿病、子宮内膜症、インスリン抵抗性、肝臓病を検出するように設計されています。このキットは、静脈血中の2-ヒドロキシ酪酸（2-HB）レベルを測定します。2-HBレベルの上昇は、還元ストレスの増加と関連しており、インスリン抵抗性を含む様々な内分泌・肥満関連疾患と関連しています。このキットはあらゆる臨床分析装置と互換性があり、わずか8分で結果が得られるため、迅速かつ効率的な診断ソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界妊娠糖尿病 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の妊娠糖尿病市場：成長率分析
• 世界の妊娠糖尿病市場の実績：規模と成長, 2019-2024
• 世界の妊娠糖尿病市場の予測：規模と成長, 2024-2029, 2034F
• 世界妊娠糖尿病総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の妊娠糖尿病市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプA1
• タイプA2
• その他のタイプ
• 世界の妊娠糖尿病市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 監視
• 薬物治療
• 非薬物治療
• 世界の妊娠糖尿病市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• その他の政権
• 世界の妊娠糖尿病市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 在宅ケア設定
• 診断センター
• 世界の妊娠糖尿病市場、タイプA1のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 食事制限妊娠糖尿病
• 運動制御妊娠糖尿病
• 世界の妊娠糖尿病市場、タイプA2のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• インスリン制御妊娠糖尿病
• 経口薬管理妊娠糖尿病
• 世界の妊娠糖尿病市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 妊娠前糖尿病
• 妊娠糖尿病複雑な機能

第7章 地域別・国別分析

• 世界の妊娠糖尿病市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の妊娠糖尿病市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 妊娠糖尿病市場：競合情勢
• 妊娠糖尿病市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Becton, Dickinson and Company
• Boehringer Ingelheim GmbH
• Dexcom Inc
• Biocon Limited
• LifeScan Inc
• Ascensia Diabetes Care Holdings AG
• Trividia Health Inc.
• Nipro Diagnostics, Inc.
• Sernova Corp.
• ZyVersa Therapeutics, Inc.
• Peptron Inc.
• Roche Diabetes Care
• DiabetOmics Inc
• Merck & Co. Inc.
• Medtronic plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 妊娠糖尿病市場2029：新たな機会を提供する国
• 妊娠糖尿病市場2029：新たな機会を提供するセグメント
• 妊娠糖尿病市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gestational diabetes is a type of diabetes that arises during pregnancy when the body fails to produce enough insulin to adequately regulate blood sugar levels. This condition usually emerges in the second or third trimester and can occur in women without a prior history of diabetes. Gestational diabetes poses risks to both the mother and the baby, including high birth weight, premature delivery, and an increased likelihood of developing type 2 diabetes later in life for both. Management typically involves adjustments to diet, regular exercise, blood sugar monitoring, and, if necessary, insulin therapy to support a healthy pregnancy and childbirth.

Gestational diabetes is categorized into several types, including Type A1, Type A2, and other forms. Type A1 refers to gestational diabetes mellitus (GDM) that develops during pregnancy due to insufficient insulin production to meet the increased demands of this period. Treatment strategies often include blood sugar monitoring, medication, and lifestyle interventions, which may be delivered orally, intravenously, or through other methods. These interventions are commonly implemented in hospitals, clinics, home care settings, and diagnostic centers.

The gestational diabetes market research report is one of a series of new reports from The Business Research Company that provides gestational diabetes market statistics, including gestational diabetes industry global market size, regional shares, competitors with gestational diabetes market share, detailed gestational diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the gestational diabetes industry. This gestational diabetes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gestational diabetes market size has grown strongly in recent years. It will grow from $8.37 billion in 2024 to $9.14 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to various factors, such as the increasing prevalence of diabetes, advancements in blood glucose measurement accuracy, a rise in the number of insurance providers, and a growing population of individuals with diabetes. Furthermore, the expanding diabetic population has played a significant role in driving this growth.

The gestational diabetes market size is expected to see strong growth in the next few years. It will grow to $12.90 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth projected for the forecast period is driven by various factors, including the increasing prevalence of obesity, greater adoption of cloud-based project solutions, and the rising use of related devices and applications. Additionally, the surge in diabetes cases due to unhealthy lifestyle choices, heightened public health awareness, and escalating diabetes rates are significant contributors. Key trends anticipated during this period include the emergence of digital diabetes management apps, closed-loop control systems, advancements in diabetes management technologies, enzymatic innovations, and other cutting-edge medical advancements.

The growing prevalence of obesity is expected to drive the expansion of the gestational diabetes market in the future. Obesity refers to individuals with a body mass index (BMI) of 30 or higher, indicating excessive body fat that can lead to significant health risks. The rise in obesity is influenced by factors such as sedentary lifestyles, the increased intake of high-calorie processed foods, genetic predispositions, and limited access to healthy food and exercise options. Gestational diabetes treatment is particularly important for the obese population, as their increased risk of insulin resistance and excessive weight gain during pregnancy can cause complications for both the mother and baby if left untreated. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental agency, reported that approximately 1 in 8 people worldwide were living with obesity in 2022. This includes 2.5 billion adults aged 18 and older classified as overweight, of which 890 million were living with obesity. Among adults, 43% were overweight, and 16% were obese. Additionally, 37 million children under 5 years old were overweight, and more than 390 million children and adolescents aged 5 to 19 years were overweight, including 160 million living with obesity. As a result, the increasing obese population is driving the growth of the gestational diabetes market.

Leading companies in the gestational diabetes market are focusing on the development of advanced products, such as diagnostic kits, to offer quick, accurate, and convenient methods for early detection of the condition. A diagnostic kit for gestational diabetes is a medical tool used to measure blood glucose levels and detect abnormal glucose tolerance in pregnant women, helping in the early identification and management of the condition. For example, in August 2024, DirectSens GmbH, a biotechnology company based in Austria, introduced the XpressGT RUO kit. This diagnostic kit is designed to detect gestational diabetes, endometriosis, insulin resistance, and liver disease. It measures 2-hydroxybutyrate (2-HB) levels in venous blood, a substance naturally produced by the liver during its normal functions. Elevated 2-HB levels are linked to increased reductive stress, which is associated with various endocrine and obesity-related disorders, including insulin resistance. The kit is compatible with any clinical analyzer and provides results in just 8 minutes, offering a fast and efficient diagnostic solution.

In April 2024, Digostics, a diabetes home-testing provider based in the UK, partnered with AgaMatrix Europe to advance gestational diabetes screening. This collaboration grants AgaMatrix exclusive rights to distribute Digostics' home oral glucose tolerance testing (OGTT) service, GTT@home, to the UK National Health Service (NHS). By utilizing its strong connections and customer base within NHS maternity services, along with its extensive expertise in gestational diabetes monitoring, AgaMatrix aims to accelerate the introduction of GTT@home in the UK market. AgaMatrix Europe is a UK-based company specializing in the production of blood glucose monitoring solutions.

Major players in the gestational diabetes market are Sanofi S.A., AstraZeneca plc, Abbott Laboratories, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Dexcom Inc, Biocon Limited, LifeScan Inc, Ascensia Diabetes Care Holdings AG, Trividia Health Inc., Nipro Diagnostics, Inc., Sernova Corp., ZyVersa Therapeutics, Inc., Peptron Inc., Roche Diabetes Care, DiabetOmics Inc, Merck & Co. Inc., Medtronic plc.

North America was the largest region in the gestational diabetes market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gestational diabetes report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gestational diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gestational diabetes market consists of revenues earned by entities by providing services such as nutritional counseling, medication management, telemedicine services, lifestyle and exercise guidance. The market value includes the value of related goods sold by the service provider or included within the service offering. The gestational diabetes market also includes sales of metformin, glyburide, and insulin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gestational Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gestational diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gestational diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gestational diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Type A1; Type A2; Other Types
• 2) By Treatment: Monitoring; Drug Treatment; Non-pharmacological treatment
• 3) By Administration: Oral; Intravenous; Other Administrations
• 4) By End User: Hospitals; Clinics; Home Care Settings; Diagnostic Centers
• Subsegments:
• 1) By Type A1: Diet-Controlled Gestational Diabetes; Exercise-Controlled Gestational Diabetes
• 2) By Type A2: Insulin-Controlled Gestational Diabetes; Oral Medication-Controlled Gestational Diabetes
• 3) By Other Types: Pre-Gestational Diabetes; Gestational Diabetes With Complications
• Companies Mentioned: Sanofi S.A.; AstraZeneca plc; Abbott Laboratories; Eli Lilly and Company; Novo Nordisk A/S
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gestational Diabetes Market Characteristics

3. Gestational Diabetes Market Trends And Strategies

4. Gestational Diabetes Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gestational Diabetes Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gestational Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gestational Diabetes Market Growth Rate Analysis
• 5.4. Global Gestational Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gestational Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gestational Diabetes Total Addressable Market (TAM)

6. Gestational Diabetes Market Segmentation

• 6.1. Global Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type A1
• Type A2
• Other Types
• 6.2. Global Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monitoring
• Drug Treatment
• Non-pharmacological treatment
• 6.3. Global Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Other Administrations
• 6.4. Global Gestational Diabetes Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings
• Diagnostic Centers
• 6.5. Global Gestational Diabetes Market, Sub-Segmentation Of Type A1, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diet-Controlled Gestational Diabetes
• Exercise-Controlled Gestational Diabetes
• 6.6. Global Gestational Diabetes Market, Sub-Segmentation Of Type A2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Insulin-Controlled Gestational Diabetes
• Oral Medication-Controlled Gestational Diabetes
• 6.7. Global Gestational Diabetes Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pre-Gestational Diabetes
• Gestational Diabetes With Complications

7. Gestational Diabetes Market Regional And Country Analysis

• 7.1. Global Gestational Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gestational Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gestational Diabetes Market

• 8.1. Asia-Pacific Gestational Diabetes Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gestational Diabetes Market

• 9.1. China Gestational Diabetes Market Overview
• 9.2. China Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gestational Diabetes Market

• 10.1. India Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gestational Diabetes Market

• 11.1. Japan Gestational Diabetes Market Overview
• 11.2. Japan Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gestational Diabetes Market

• 12.1. Australia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gestational Diabetes Market

• 13.1. Indonesia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gestational Diabetes Market

• 14.1. South Korea Gestational Diabetes Market Overview
• 14.2. South Korea Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gestational Diabetes Market

• 15.1. Western Europe Gestational Diabetes Market Overview
• 15.2. Western Europe Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gestational Diabetes Market

• 16.1. UK Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gestational Diabetes Market

• 17.1. Germany Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gestational Diabetes Market

• 18.1. France Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gestational Diabetes Market

• 19.1. Italy Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gestational Diabetes Market

• 20.1. Spain Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gestational Diabetes Market

• 21.1. Eastern Europe Gestational Diabetes Market Overview
• 21.2. Eastern Europe Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gestational Diabetes Market

• 22.1. Russia Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gestational Diabetes Market

• 23.1. North America Gestational Diabetes Market Overview
• 23.2. North America Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gestational Diabetes Market

• 24.1. USA Gestational Diabetes Market Overview
• 24.2. USA Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gestational Diabetes Market

• 25.1. Canada Gestational Diabetes Market Overview
• 25.2. Canada Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gestational Diabetes Market

• 26.1. South America Gestational Diabetes Market Overview
• 26.2. South America Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gestational Diabetes Market

• 27.1. Brazil Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gestational Diabetes Market

• 28.1. Middle East Gestational Diabetes Market Overview
• 28.2. Middle East Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gestational Diabetes Market

• 29.1. Africa Gestational Diabetes Market Overview
• 29.2. Africa Gestational Diabetes Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gestational Diabetes Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gestational Diabetes Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gestational Diabetes Market Competitive Landscape And Company Profiles

• 30.1. Gestational Diabetes Market Competitive Landscape
• 30.2. Gestational Diabetes Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novo Nordisk A/S Overview, Products and Services, Strategy and Financial Analysis

31. Gestational Diabetes Market Other Major And Innovative Companies

• 31.1. Becton, Dickinson and Company
• 31.2. Boehringer Ingelheim GmbH
• 31.3. Dexcom Inc
• 31.4. Biocon Limited
• 31.5. LifeScan Inc
• 31.6. Ascensia Diabetes Care Holdings AG
• 31.7. Trividia Health Inc.
• 31.8. Nipro Diagnostics, Inc.
• 31.9. Sernova Corp.
• 31.10. ZyVersa Therapeutics, Inc.
• 31.11. Peptron Inc.
• 31.12. Roche Diabetes Care
• 31.13. DiabetOmics Inc
• 31.14. Merck & Co. Inc.
• 31.15. Medtronic plc

32. Global Gestational Diabetes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gestational Diabetes Market

34. Recent Developments In The Gestational Diabetes Market

35. Gestational Diabetes Market High Potential Countries, Segments and Strategies

• 35.1 Gestational Diabetes Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gestational Diabetes Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gestational Diabetes Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer